EpiBiologics
Developing antibody-based therapies to degrade disease-driving membrane proteins.
Company facts
- Founded
- 2020
- Employees
- 47
- Headquarters
- United States
- Type
- Private
- Funding
- Series B · $107M · 2026
Developing antibody-based therapies to degrade disease-driving membrane proteins.
Company facts